Cover
Cover | 6 Months Ended |
Jun. 30, 2021 | |
Cover [Abstract] | |
Document Type | S-4 |
Amendment Flag | false |
Entity Registrant Name | Big Cypress Acquisition Corp. |
Entity Central Index Key | 0001833214 |
Entity Tax Identification Number | 85-3899721 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 300 W. 41st Street |
Entity Address, Address Line Two | Suite 202 |
Entity Address, City or Town | Miami Beach |
Entity Address, State or Province | FL |
Entity Address, Postal Zip Code | 33140 |
City Area Code | (305) |
Local Phone Number | 204-3338 |
Entity Filer Category | Non-accelerated Filer |
Entity Small Business | true |
Entity Emerging Growth Company | true |
Elected Not To Use the Extended Transition Period | false |
Condensed Balance Sheets
Condensed Balance Sheets - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 | |
Assets: | |||
Cash | $ 756,803 | $ 84,836 | |
Prepaid Expenses | 179,867 | 2,258 | |
Total current assets | 936,670 | 87,094 | |
Deferred offering costs | 235,111 | ||
Marketable securities held in Trust Account | 116,155,315 | ||
Total assets | 117,091,985 | 322,205 | |
Liabilities and Stockholders’ Equity | |||
Accrued offering costs and expenses | 152,879 | 156,201 | |
Promissory note – related party | 150,000 | ||
Total current liabilities | 152,879 | 306,201 | |
Deferred underwriting fee | 4,220,500 | ||
Warrant liability | 5,531,106 | ||
Total liabilities | 9,904,485 | 306,201 | |
Commitments and Contingencies | |||
Common Stock subject to possible redemption, 10,117,574 and no shares at redemption value at June 30, 2021 and December 31, 2020, respectively | 102,187,499 | ||
Stockholders’ Equity: | |||
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding | |||
Common stock, $0.0001 par value; 50,000,000 shares authorized;4,674,626 and 2,875,000 shares issued and outstanding (excluding 10,117,574 and no shares subject to possible redemption) at June 30, 2021 and December 31, 2020, respectively | 467 | 288 | [1] |
Additional paid-in capital | 4,237,471 | 24,712 | |
Accumulated deficit | 762,063 | (8,996) | |
Total stockholders’ equity | 5,000,001 | 16,004 | |
Total Liabilities and Stockholders’ Equity | $ 117,091,985 | $ 322,205 | |
[1] | Includes up to 343,125 31,875 ). As a result of the underwriter’s election to fully exercise their over-allotment option on January 14, 2021, the founder shares and representative shares are no longer subject to forfeiture (see Note 8). |
Condensed Balance Sheets (Paren
Condensed Balance Sheets (Parenthetical) - $ / shares | 2 Months Ended | |
Dec. 31, 2020 | Jun. 30, 2021 | |
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items] | ||
Redemption value | 0 | 10,117,574 |
Preferred stock, par value | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 1,000,000 | 1,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 50,000,000 | 50,000,000 |
Common stock, shares issued | 2,875,000 | 4,674,626 |
Common stock, shares outstanding | 2,875,000 | 4,674,626 |
Shares subject to forfeiture | 375,000 | |
Sponsor [Member] | Maximum [Member] | ||
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items] | ||
Shares subject to forfeiture | 343,125 | |
Ladenburg and Certain Employees [Member] | Maximum [Member] | ||
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items] | ||
Shares subject to forfeiture | 31,875 |
Condensed Statement of Operatio
Condensed Statement of Operations - USD ($) | 2 Months Ended | 3 Months Ended | 6 Months Ended | |||
Dec. 31, 2020 | Jun. 30, 2021 | Jun. 30, 2021 | ||||
Income Statement [Abstract] | ||||||
Formation and operating costs | $ 8,996 | $ 256,847 | $ 368,459 | |||
Loss from Operations | (256,847) | (368,459) | ||||
Other income (expense): | ||||||
Interest earned on marketable securities held in Trust Account | 2,896 | 5,315 | ||||
Offering costs allocated to warrants | (359,874) | |||||
Change in fair value of warrant liability | (1,948,210) | 1,494,077 | ||||
Total other income (expense) | (1,945,314) | 1,139,518 | ||||
Net loss | $ (8,996) | $ (2,202,161) | $ 771,059 | |||
Basic and diluted weighted average shares outstanding (1) | 2,500,000 | [1] | 4,443,103 | [2] | 4,162,957 | [2] |
Basic and diluted net loss per share, Common stock | $ 0 | $ (0.50) | $ 0.18 | |||
[1] | Excludes up to 343,125 31,875 As a result of the underwriter’s election to fully exercise their over-allotment option on January 14, 2021, the founder shares and representative shares are no longer subject to forfeiture (see Note 8). | |||||
[2] | Excludes an aggregate of 10,117,574 |
Condensed Statement of Operat_2
Condensed Statement of Operations (Parenthetical) | Jun. 30, 2021shares |
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items] | |
Redemption value | 10,117,574 |
Condensed Statements of Changes
Condensed Statements of Changes in Stockholders' Equity - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total | |
Balance at Nov. 11, 2020 | |||||
Balance, shares at Nov. 11, 2020 | [1] | 0 | |||
Common stock issued to Sponsor | $ 288 | 24,712 | 25,000 | ||
Common stock issued to Sponsor, shares | [1] | 2,875,000 | |||
Net loss | (8,996) | (8,996) | |||
Balance at Dec. 31, 2020 | $ 288 | 24,712 | (8,996) | 16,004 | |
Balance, shares at Dec. 31, 2020 | [1] | 2,875,000 | |||
Sale of 11,500,000 Units, net of underwriting discount and offering expenses | $ 1,150 | 109,250,365 | 109,251,515 | ||
Sale of 11,500,000 Units, net of underwriting discount and offering expenses, shares | 11,500,000 | ||||
Sale of 417,200 Private Placement Units | $ 42 | 4,171,958 | 4,172,000 | ||
Sale of 417,200 Private Units, shares | 417,200 | ||||
Proceeds received from sale of shares to representative | 2,105 | 2,105 | |||
Initial recognition of warrant liability | (7,025,183) | (7,025,183) | |||
Common stock subject to possible redemption | $ (1,035) | (104,388,621) | (104,389,656) | ||
Common stock subject to possible redemption, shares | (10,117,574) | ||||
Net loss | 2,973,220 | 2,973,220 | |||
Balance at Mar. 31, 2021 | $ 445 | 2,035,336 | 2,964,224 | 5,000,005 | |
Balance, shares at Mar. 31, 2021 | 4,456,591 | ||||
Balance at Dec. 31, 2020 | $ 288 | 24,712 | (8,996) | 16,004 | |
Balance, shares at Dec. 31, 2020 | [1] | 2,875,000 | |||
Net loss | 771,059 | ||||
Balance at Jun. 30, 2021 | $ 467 | 4,237,471 | 762,063 | 5,000,001 | |
Balance, shares at Jun. 30, 2021 | 4,674,626 | ||||
Balance at Mar. 31, 2021 | $ 445 | 2,035,336 | 2,964,224 | 5,000,005 | |
Balance, shares at Mar. 31, 2021 | 4,456,591 | ||||
Common stock subject to possible redemption | $ 22 | 2,202,135 | 2,202,157 | ||
Common stock subject to possible redemption, shares | 218,035 | ||||
Net loss | (2,202,161) | (2,202,161) | |||
Balance at Jun. 30, 2021 | $ 467 | $ 4,237,471 | $ 762,063 | $ 5,000,001 | |
Balance, shares at Jun. 30, 2021 | 4,674,626 | ||||
[1] | Includes up to 343,125 31,875 ). As a result of the underwriter’s election to fully exercise their over-allotment option on January 14, 2021, the founder shares and representative shares are no longer subject to forfeiture (see Note 8). |
Condensed Statements of Chang_2
Condensed Statements of Changes in Stockholders' Equity (Parenthetical) - shares | 2 Months Ended | 6 Months Ended |
Dec. 31, 2020 | Jun. 30, 2021 | |
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items] | ||
Sale of units | 11,500,000 | |
Sale of Private Units | 417,200 | |
Shares subject to forfeiture | 375,000 | |
Sponsor [Member] | Maximum [Member] | ||
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items] | ||
Shares subject to forfeiture | 343,125 | |
Ladenburg and Certain Employees [Member] | Maximum [Member] | ||
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items] | ||
Shares subject to forfeiture | 31,875 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows - USD ($) | 2 Months Ended | 6 Months Ended |
Dec. 31, 2020 | Jun. 30, 2021 | |
Cash flows from operating activities: | ||
Net loss | $ (8,996) | $ 771,059 |
Adjustments to reconcile net income to net cash used in operating activities: | ||
Interest earned on marketable securities held in Trust Account | (5,315) | |
Offering costs allocated to warrants | 359,874 | |
Change in fair value of warrant liability | (1,494,077) | |
Changes in operating assets and liabilities: | ||
Prepaid assets | (2,558) | (177,609) |
Accrued expenses | 1,222 | 81,657 |
Net cash used in operating activities | (10,032) | (464,411) |
Cash Flows from Investing Activities: | ||
Investment of cash in Trust Account | (116,150,000) | |
Net cash used in investing activities | (116,150,000) | |
Cash Flows from Financing Activities: | ||
Proceeds from sale of Units, net of underwriting discounts | 113,470,500 | |
Proceeds from sale of Private Placement Units | 4,172,000 | |
Proceeds from sale of representative shares | 2,105 | |
Repayment of promissory note – related party | (150,000) | |
Payment of deferred offering costs | (80,132) | (208,227) |
Net cash provided by financing activities | 94,868 | 117,286,378 |
Net change in cash | 84,836 | 671,967 |
Cash, beginning of period | 84,836 | |
Cash, end of the period | 84,836 | 756,803 |
Supplemental disclosure of cash flow information: | ||
Initial value of common stock subject to possible redemption | 101,131,827 | |
Change in initial value of common stock subject to possible redemption | 1,055,672 | |
Initial recognition of warrant liability | 7,025,183 | |
Deferred underwriters’ discount payable charged to additional paid-in capital | 4,220,500 | |
Change in accrued offering costs | $ 84,979 | |
Proceeds from issuance of founder shares | 25,000 | |
Proceeds from issuance of promissory note to related party | 150,000 | |
Deferred offering costs included in accrued offering costs and expenses | $ 154,979 |
Organization and Business Opera
Organization and Business Operations | 2 Months Ended | 6 Months Ended |
Dec. 31, 2020 | Jun. 30, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Organization and Business Operations | Note 1 — Organization and Business Operations Big Cypress Acquisition Corp. (the “Company”) is a newly organized blank check company incorporated in Delaware on November 12, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (“Business Combination”). The Company has not selected any specific business combination target and the Company has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target with respect to the Business Combination . As of December 31, 2020, the Company had not commenced any operations. All activity for the period from November 12, 2020 (inception) through December 31, 2020 relates to the Company’s formation and preparation for the Initial Public Offering (“IPO”) as described below. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering as described below. The Company has selected December 31 as its fiscal year end. The Company’s sponsor is Big Cypress Holdings LLC, a Delaware limited liability company (the “Sponsor”). Subsequent to December 31, 2020, the registration statement for the Company’s IPO was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on January 11, 2021 (the “Effective Date”). On January 14, 2021, the Company 11,500,000 1,500,000 10.00 115,000,000 417,200 10.00 4,172,000 Each Unit consists of one share of common stock, and one-half redeemable warrant to purchase one share of common stock at a price of $ 11.50 Transaction costs of the IPO amounted to $ 6,038,360 1,529,500 4,220,500 288,360 Following the closing of the IPO on January 14, 2021, $ 116,150,000 10.10 The Company will provide its public stockholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial business combination either (i) in connection with a stockholder meeting called to approve the initial business combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed initial business combination or conduct a tender offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem their shares for a pro rata portion of the amount then on deposit in the Trust Account (initially approximately $10.10 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The shares of common stock subject to redemption will be recorded at a redemption value and classified as temporary equity upon the completion of the IPO, in accordance with Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination. The Company will have 15 months (or up to 21 months) from the closing of the IPO to consummate a Business Combination (the “Combination Period”). However, if the Company is unable to complete a Business Combination within the Combination Period, the Company will redeem 100% of the outstanding public shares for a pro rata portion of the funds held in the trust account, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to the Company to pay its franchise and income taxes, divided by the number of then outstanding public shares, subject to applicable law and as further described in registration statement, and then seek to dissolve and liquidate. The Sponsor, officers and directors have agreed to (i) waive their redemption rights with respect to their founder shares and placement shares in connection with the completion of the initial business combination, (ii) waive their redemption rights with respect to their founder shares and placement shares in connection with a stockholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation, and (iii) waive their rights to liquidating distributions from the trust account with respect to their founder shares and placement shares if the Company fails to complete the initial business combination within the Combination Period. The Company’s Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or business combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account, if less than $10.00 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of this offering against certain liabilities, including liabilities under the Securities Act. However, the Company has not asked its Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether its Sponsor has sufficient funds to satisfy its indemnity obligations and believe that the Company’s Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure that its Sponsor would be able to satisfy those obligations. Liquidity and Capital Resources As of December 31, 2020, the Company had $ 84,836 219,107 25,000 150,000 Subsequent to December 31, 2020, on January 14, 2021, simultaneous with the consummation of the IPO, the net proceeds from the consummation of the Private Placement not held in Trust were deposited into the Company’s operating bank account (see Note 8). As of January 14, 2021, the Company had approximately $ 1.2 1.2 Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. Risks and Uncertainties Management continuing to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that it could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. | Note 1 — Organization and Business Operations Big Cypress Acquisition Corp. (the “Company”) is a newly organized blank check company incorporated in Delaware on November 12, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (“Business Combination”). As of June 30, 2021, the Company had not commenced any operations. All activity through June 30, 2021 relates to the Company’s formation and the Initial Public Offering (“IPO”) which is described below, and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering and income/expense from change in fair value of warrant liability. The registration statement for the Company’s IPO was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on January 11, 2021 (the “Effective Date”). On January 14, 2021, the Company consummated the IPO of 11,500,000 1,500,000 10.00 115,000,000 Each Unit consists of one share of common stock, and one-half redeemable warrant to purchase one share of common stock at a price of $ 11.50 Simultaneously with the closing of the IPO, the Company consummated the sale of 417,200 10.00 4,172,000 Transaction costs of the IPO amounted to $ 6,108,360 1,529,500 4,220,500 358,360 359,874 Following the closing of the IPO on January 14, 2021, $ 116,150,000 100,000 The Company will provide its public stockholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial business combination either (i) in connection with a stockholder meeting called to approve the initial business combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed initial business combination or conduct a tender offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem their shares for a pro rata portion of the amount then on deposit in the Trust Account (initially approximately $ 10.10 The Company will have 15 months (or up to 21 months) from the closing of the IPO on January 14, 2021 to consummate a Business Combination (the “Combination Period”). However, if the Company is unable to complete a Business Combination within the Combination Period,the Company will redeem 100% of the outstanding public shares for a pro rata portion of the funds held in the trust account, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to the Company to pay its franchise and income taxes, divided by the number of then outstanding public shares, subject to applicable law and as further described in the registration statement, and then seek to dissolve and liquidate. The Sponsor, officers and directors have agreed to (i) waive their redemption rights with respect to their founder shares and placement shares in connection with the completion of the initial business combination, (ii) waive their redemption rights with respect to their founder shares and placement shares in connection with a stockholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation, and (iii) waive their rights to liquidating distributions from the trust account with respect to their founder shares and placement shares if the Company fails to complete the initial business combination within the Combination Period. In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or business combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $ 10.00 per public share and (ii) the actual amount per public share held in the trust account as of the date of the liquidation of the trust account, if less than $10.00 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the trust account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of this offering against certain liabilities, including liabilities under the Securities Act. However, the Company has not asked its Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether its Sponsor has sufficient funds to satisfy its indemnity obligations and believes that the Company’s Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure that its Sponsor would be able to satisfy those obligations. Risks and Uncertainties Management is continuing to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that it could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Business Combination Agreement On June 21, 2021, the Company, entered into a business combination agreement (the “Business Combination Agreement”) by and among the Company, Big Cypress Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Merger Sub”) SAB Biotherapeutics, Inc., a Delaware corporation (“SAB”) and Shareholder Representative Services LLC, as the stockholder representative to the SAB stockholders. The Business Combination Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into SAB, with SAB surviving as a wholly-owned subsidiary of the Company (the “Merger”). Upon the closing of the Business Combination (the “Closing”), it is anticipated that the Company will change its name to “SAB Biotherapeutics, Inc.” (“New SAB”). The Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the “Business Combination.” The Business Combination is expected to close in the fourth quarter of 2021, following the receipt of the required approval by the Company’s stockholders and the fulfilment of other customary closing conditions. In accordance with the terms and subject to the conditions of the Business Combination Agreement, prior to the effective time of the Merger (the “ Effective Time SAB Shares 0.0001 Company New Shares 300.0 In addition to the foregoing consideration, SAB stockholders shall be entitled to receive, as additional consideration, and without any action on behalf of the Company, Merger Sub, or the Company’s stockholders, approximately ____ additional Company New Shares (the “ Earnout Shares Earnout Period (A) 25% of the Earnout Shares, if the VWAP (as defined in the Business Combination Agreement) of Company Shares is greater than or equal to $15.00 for any twenty (20) Trading Days (as defined in the Business Combination Agreement) within a period of thirty (30) consecutive Trading Days, (B) 25% of the Earnout Shares, if the VWAP of Company Shares is greater than or equal to $20.00 for any twenty (20) Trading Days within a period of thirty (30) consecutive Trading Days, (C) 25% of the Earnout Shares, if the VWAP of Company Shares is greater than or equal to $25.00 for any twenty (20) Trading Days within a period of thirty (30) consecutive Trading Days, and (D) 25% of the Earnout Shares, if the VWAP of Company Shares is greater than or equal to $30.00 for any twenty (20) Trading Days within a period of thirty (30) consecutive Trading Days. The Business Combination Agreement may be terminated under certain customary and limited circumstances described in the Business Combination Agreement, including, without limitation, each party’s right to terminate, subject to certain limited exceptions, if the Business Combination is not consummated by December 15, 2021. If the Business Combination Agreement is validly terminated, none of the parties to the Business Combination Agreement will have any liability with respect to the other parties to the Business Combination Agreement or any further obligation under the Business Combination Agreement, other than customary confidentiality obligations, except in the case of Willful Breach or Fraud (each, as defined in the Business Combination Agreement). |
Restatement of Previously Issue
Restatement of Previously Issued Financial Statements | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Changes and Error Corrections [Abstract] | |
Restatement of Previously Issued Financial Statements | Note 2 — Restatement of Previously Issued Financial Statements In April 2021, the Company concluded that, because of a misapplication of the accounting guidance related to its Public and Private Placement warrants the Company issued in January 2021, the Company’s previously issued balance sheet as of January 14, 2021 on Form 8-K filed with SEC on January 21, 2021 should no longer be relied upon. As such, the Company restated its balance sheet included in that Form 8-K as shown below. On April 12, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”)” (the “SEC Staff Statement”). In the SEC Staff Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity. Since issuance on January 14, 2021, the Company’s warrants were accounted for as equity within the Company’s previously reported balance sheet, and after discussion and evaluation, management, in consultation with its Audit Committee, concluded that the warrants should be presented as liabilities with subsequent fair value remeasurement. Historically, the Warrants were reflected as a component of equity as opposed to liabilities on the balance sheets and the statements of operations did not include the subsequent non-cash changes in estimated fair value of the Warrants, based on our application of FASB ASC Topic 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity (“ASC 815-40). The views expressed in the SEC Staff Statement were not consistent with the Company’s historical interpretation of the specific provisions within its warrant agreement and the Company’s application of ASC 815-40 to the warrant agreement. The Company reassessed its accounting for Warrants issued on January 14, 2021, in light of the SEC Staff’s published views. Based on this reassessment, management determined that the Warrants should be classified as liabilities measured at fair value upon issuance, with subsequent changes in fair value reported in the Company Statement of Operations each reporting period. Impact of the Restatement The impact to the balance sheet dated January 14, 2021, filed on Form 8-K on January 21, 2021 related to the impact of accounting for public and private warrants as liabilities at fair value resulted in a $ 7.0 355,750 Schedule of Restatement of Balance Sheet As of January 14, 2021 As Previously Restatement As Restated Balance Sheet as of January 14, 2021 Total assets $ 117,645,054 $ — $ 117,645,045 Liabilities and stockholders’ equity Total current liabilities $ 267,540 $ — $ 267,540 Stock warrant liabilities — 7,025,183 7,025,183 Total liabilities $ 4,488,040 7,025,183 11,513,223 Class A common stock, $ 0.0001 108,157,010 (7,025,183 ) 101,131,827 Stockholders’ equity Preferred stock- $ 0.0001 — — — Common stock - $ 0.0001 398 81 479 Additional paid-in-capital 5,003,838 355,669 5,359,507 Accumulated deficit (4,232 ) (355,750 ) (359,982 ) Total stockholders’ equity 5,000,004 — 5,000,004 Total liabilities and stockholders’ equity $ 117,645,054 $ — $ 117,645,054 |
Significant Accounting Policies
Significant Accounting Policies | 2 Months Ended | 6 Months Ended |
Dec. 31, 2020 | Jun. 30, 2021 | |
Accounting Policies [Abstract] | ||
Significant Accounting Policies | Note 2 — Significant Accounting Policies Basis of Presentation The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did no Deferred Offering Costs Deferred offering costs consist of legal, accounting and other expenses incurred through the balance sheet date that are directly related to the IPO and that will be charged to stockholders’ equity upon the completion of the IPO. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. Net Loss Per Common Stock Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. Weighted average shares were reduced for the effect of an aggregate of 375,000 As a result of the underwriter’s election to fully exercise their over-allotment option on January 14, 2021, the 375,000 Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. The deferred tax assets were deemed to be de minimus as of December 31, 2020. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only “major” tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The provision for income taxes was deemed to be de minimus for the period from November 12, 2020 (inception) through December 31, 2020. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the federal depository insurance coverage of $ 250,000 Recent Accounting Pronouncements Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements. | Note 3 — Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on April 2, 2021, which contains the audited financial statements and notes thereto. The interim results for the three months and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did no Marketable Securities Held in Trust Account At June 30, 2021, substantially all of the assets held in the Trust Account were held in money market funds which invest in U.S. Treasury securities. Warrant Liabilities The Company evaluated the Public Warrants and Private Placement Warrants (collectively, “Warrants”, which are discussed in Note 2, Note 4, Note 5 and Note 9) in accordance with ASC 815-40, “Derivatives and Hedging — Contracts in Entity’s Own Equity”, and concluded that a provision in the Warrant Agreement related to certain tender or exchange offers precludes the Warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as derivative liabilities on the Condensed Balance Sheet and measured at fair value at inception (on the date of the IPO) and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in the Condensed Statement of Operations in the period of change. Offering Costs Associated with the Initial Public Offering The Company complies with the requirements of the ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred, presented as non-operating expenses in the statement of operations. Offering costs associated with the Class A common stock were charged to stockholders’ equity upon the completion of the Initial Public Offering. Transaction costs for the six month ended June 30, 2021 amounted to $ 6,108,360 359,874 Common Stock Subject to Possible Redemption The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s condensed balance sheets. Income Taxes The Company accounts for income taxes under ASC 740, Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. The deferred tax assets were deemed to be de minimis as of June 30, 2021 and December 31, 2020. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no Net Income Per Common Share Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The Company applies the two-class method in calculating earnings per share. Shares of common stock subject to possible redemption at June 30, 2021, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of basic net loss per common share since such shares, if redeemed, only participate in their pro rata share of the Trust Account earnings, less the Company’s portion available to pay taxes. The Company has not considered the effect of warrants sold in the Initial Public Offering and the private placement to purchase 5,958,600 Net Income per Common Share The Company’s net income is adjusted for the portion of income that is attributable to common stock subject to possible redemption, as these shares only participate in the earnings of the Trust Account and not the income or losses of the Company. Accordingly, basic and diluted loss per common share is calculated as follows: Schedule of Reconciliation of Net Income Per Common Share Three Months Six Months Common Stock Subject to Possible Redemption Numerator: Earnings allocable to common stock subject to possible redemption Interest earned on marketable securities held in Trust Account $ 2,896 $ 5,315 Less: Interest allocable to non-redeemable common stock (915 ) (1,680 ) Net income allocable to shares subject to possible redemption $ 1,981 $ 3,635 Denominator: Weighted Average Redeemable Class A Ordinary Shares Basic and diluted weighted average shares outstanding 10,333,213 10,363,269 Basic and diluted net income per share $ 0.00 $ 0.00 Non-Redeemable Common Stock Numerator: Net Income (Loss) Minus Net Earnings Net Income (Loss) $ (2,202,161 ) $ 771,059 Less: Income attributable to common stock subject to possible redemption (1,981 ) (3,635 ) Non-Redeemable net income (loss) $ (2,204,142 ) $ 767,424 Weighted average non-redeemable shares outstanding, basic and diluted 4,443,103 4,162,957 Basic and diluted net income (loss) per share $ (0.50 ) $ 0.18 Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the federal depository insurance coverage of $ 250,000 Fair Value of Financial Instruments The Company follows the guidance in ASC 820, “Fair Value Measurement,” for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment. Level 2 — Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means. Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement. See Note 9 for additional information on assets and liabilities measured at fair value. Recently Adopted Accounting Standards In August 2020, the FASB issued ASU 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company early adopted ASU 2020-06 on January 1, 2021. Adoption of the ASU did not impact the Company’s financial position, results of operations or cash flows. Recent Accounting Pronouncements Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements. |
Initial Public Offering
Initial Public Offering | 2 Months Ended | 6 Months Ended |
Dec. 31, 2020 | Jun. 30, 2021 | |
Initial Public Offering | ||
Initial Public Offering | Note 3 — Initial Public Offering On January 14, 2021, the Company sold 11,500,000 10.00 1,500,000 11.50 | Note 4 — Initial Public Offering Public Units On January 14, 2021, the Company sold 11,500,000 10.00 1,500,000 10.00 Each Unit consists of one share of common stock, and one-half warrant to purchase one share of common stock (the “Public Warrants”). Public Warrants Each whole warrant entitles the holder to purchase one share of the Company’s common stock at a price of $ 11.50 In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Company’s sponsor or its affiliates, without taking into account any founder shares held by the Company’s sponsor or its affiliates, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination on the date of the consummation of the initial business combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial business combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. The Company will not be obligated to deliver any shares of common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of common stock underlying the warrants is then effective and a prospectus is current. No warrant will be exercisable and the Company will not be obligated to issue shares of common stock upon exercise of a warrant unless common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the share of common stock underlying such unit. Once the warrants become exercisable, the Company may call the warrants for redemption: ● in whole and not in part; ● at a price of $ 0.01 ● upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and ● if, and only if, the reported last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption to the warrant holders. If the Company calls the warrants for redemption as described above, the management will have the option to require any holder that wishes to exercise its warrant to do so on a “cashless basis.” If the management exercises this option, all holders of warrants would pay the exercise price by surrendering their warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the excess of the “fair market value” (defined below) over the exercise price of the warrants by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. |
Private Placement
Private Placement | 2 Months Ended | 6 Months Ended |
Dec. 31, 2020 | Jun. 30, 2021 | |
Private Placement | ||
Private Placement | Note 4 — Private Placement Simultaneously with the closing of the IPO, the Sponsor purchased 417,200 10.00 4,172,000 Each Placement Unit was identical to the Units sold in the IPO, except for the placement warrants (“Placement Warrants”) (see Note 7). If the Company does not complete its initial business combination within 15 months (or up to 21 months) from the closing of this IPO, the proceeds from the sale of the Placement Units held in the trust account will be used to fund the redemption of its public shares (subject to the requirements of applicable law) and the Placement Warrants will expire worthless. | Note 5 — Private Placement Simultaneously with the closing of the IPO, the Sponsor purchased an aggregate of 417,200 10.00 4,172,000 Each Placement Unit was identical to the Units sold in the IPO, except for the placement warrants (“Placement Warrants”). The Placement Warrants and the common stock issuable upon the exercise of the Placement Warrants will not be transferable, assignable or saleable until after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. If the Company does not complete its initial business combination within 15 months (or up to 21 months) from the closing of this IPO, the proceeds from the sale of the Placement Units held in the trust account will be used to fund the redemption of its public shares (subject to the requirements of applicable law) and the Placement Warrants will expire. |
Related Party Transactions
Related Party Transactions | 2 Months Ended | 6 Months Ended |
Dec. 31, 2020 | Jun. 30, 2021 | |
Related Party Transactions [Abstract] | ||
Related Party Transactions | Note 5 — Related Party Transactions Founder Shares On November 12, 2020, the Company issued 2,156,250 25,000 0.012 161,719 161,719 0.012 1,875 On January 3, 2021, the Company effected a stock dividend of 1/3 of a share of common stock for every share of common stock outstanding, resulting in an aggregate of 2,875,000 375,000 375,000 (see Note 7). On January 4, 2021, the Sponsor forfeited 28,750 28,750 0.008 230 2,630,625 The Sponsor has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. Representative Shares On December 7, 2020, the Sponsor forfeited 161,719 161,719 0.012 1,875 28,750 28,750 0.008 230 244,375 31,875 31,875 Ladenburg and certain of its employees have entered into a subscription agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their representative shares, as applicable, and public shares in connection with the completion of our initial business combination, (ii) waive their redemption rights with respect to their representative shares, as applicable, (iii) waive their rights to liquidating distributions from the trust account with respect to their representative shares if the Company fails to complete the initial business combination within the Combination Period. Promissory Note — Related Party On November 19, 2020, Company issued an unsecured promissory note to the Sponsor for an aggregate of up to $ 250,000 This loan is non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the IPO. 150,000 Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000 of such Working Capital Loans may be convertible into units at a price of $10.00 per unit at the option of the lender, upon consummation of the Company’s Initial Business Combination. Administrative Service Fee The Company has agreed to pay an affiliate of the Company’s Sponsor a monthly fee of an aggregate of $ 10,000 7,742 | Note 6 — Related Party Transactions Founder Shares On November 12, 2020, the Company issued 2,156,250 25,000 0.012 161,719 161,719 0.012 1,875 On January 3, 2021, the Company effected a stock dividend of 1/3 of a share of common stock for every share of common stock outstanding, resulting in an aggregate of 2,875,000 375,000 375,000 As discussed further below, on January 4, 2021, the Sponsor forfeited 28,750 28,750 230 2,630,625 The Sponsor has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. Representative Shares On December 7, 2020, the Sponsor forfeited 161,719 161,719 0.012 1,875 28,750 28,750 0.008 230 244,375 31,875 31,875 Ladenburg and certain of its employees have entered into a subscription agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their representative shares, as applicable, and public shares in connection with the completion of our initial business combination, (ii) waive their redemption rights with respect to their representative shares, as applicable, (iii) waive their rights to liquidating distributions from the trust account with respect to their representative shares if the Company fails to complete the initial business combination within the Combination Period. Promissory Note — Related Party On November 19, 2020, Company issued an unsecured promissory note to the Sponsor for an aggregate of up to $ 250,000 This loan was non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the IPO. 150,000 Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay the Working Capital Loans but no proceeds from the Trust Account would be used to repay the Working Capital Loans. Up to $1,500,000 of such Working Capital Loans may be convertible into units at a price of $10.00 per unit at the option of the lender, upon consummation of the Company’s Initial Business Combination. Administrative Service Fee The Company has agreed to pay an affiliate of the Company’s Sponsor a monthly fee of an aggregate of $ 10,000 30,000 60,000 |
Commitments and Contingencies
Commitments and Contingencies | 2 Months Ended | 6 Months Ended |
Dec. 31, 2020 | Jun. 30, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | ||
Commitments and Contingencies | Note 6 — Commitments and Contingencies Underwriting Agreement The underwriter had a 45-day option from the date of the IPO to purchase up to an aggregate of 1,500,000 underwriter fully exercised its over-allotment option (see Note 8). The underwriter was entitled to a cash underwriting fee of 1.33 1,529,500 The underwriters are entitled to deferred underwriting fee of 3.67 4,220,500 Registration Rights The holders of the founder shares, representative shares, placement units, and units that may be issued upon conversion of working capital loans will have registration rights to require the Company to register a sale of any of its securities held by them pursuant to a registration rights agreement to be signed prior to or on the effective date of this offering. These holders will be entitled to make up to three demands, excluding short form registration demands, that the Company registers such securities for sale under the Securities Act. In addition, these holders will have “piggy-back” registration rights to include their securities in other registration statements filed by the Company. The Company will bear the expenses incurred in connection with the filing of any such registration statements. | Note 7 — Commitments and Contingencies Underwriting Agreement The underwriter had a 45-day option from the date of the IPO to purchase up to an aggregate of 1,500,000 Upon consummation of the IPO on January 14, 2021, the underwriters were paid a cash underwriting fee of 1.33 1,529,500 The underwriters are entitled to a deferred underwriting fee of 3.67 4,220,500 Registration Rights The holders of the founder shares, representative shares, placement units, and units that may be issued upon conversion of working capital loans will have registration rights to require the Company to register a sale of any of its securities held by them pursuant to a registration rights agreement to be signed prior to or on the effective date of this offering. These holders will be entitled to make up to three demands, excluding short form registration demands, that the Company registers such securities for sale under the Securities Act. In addition, these holders will have “piggy-back” registration rights to include their securities in other registration statements filed by the Company. The Company will bear the expenses incurred in connection with the filing of any such registration statements. |
Stockholders_ Equity
Stockholders’ Equity | 2 Months Ended | 6 Months Ended |
Dec. 31, 2020 | Jun. 30, 2021 | |
Equity [Abstract] | ||
Stockholders’ Equity | Note 7 — Stockholders’ Equity Preferred Stock 1,000,000 0.0001 no Common Stock 50,000,000 0.0001 2,156,250 25,000 0.012 161,719 161,719 0.012 1,875 On January 3, 2021, the Company effected a stock dividend of 1/3 of a share of common stock for every share of common stock outstanding, resulting in an aggregate of 2,875,000 375,000 28,750 28,750 0.008 230 2,630,625 244,375 343,125 31,875 375,000 The Company’s initial stockholder has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and not to transfer, assign or sell the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. Any permitted transferees will be subject to the same restrictions and other agreements of the Company’s initial stockholders with respect to any founder shares. Warrants 11.50 In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Company’s Sponsor or its affiliates, without taking into account any founder shares held by the Company’s Sponsor or its affiliates, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination on the date of the consummation of the initial business combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial business combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. The warrants will become exercisable on the later of 12 months from the closing of this offering or 30 days after the completion of its initial business combination, and will expire five years after the completion of the Company’s initial business combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. The Company will not be obligated to deliver any shares of common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of common stock underlying the warrants is then effective and a prospectus is current. No warrant will be exercisable and the Company will not be obligated to issue shares of common stock upon exercise of a warrant unless common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the share of common stock underlying such unit . Once the warrants become exercisable, the Company may call the warrants for redemption: ● in whole and not in part; ● at a price of $ 0.01 ● upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and ● if, and only if, the reported last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before the Company send the notice of redemption to the warrant holders. The Placement Warrants will be identical to the Public Warrants underlying the Units being sold in the IPO, except that the Placement Warrants and the common stock issuable upon the exercise of the Placement Warrants will not be transferable, assignable or saleable until after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. If the Company calls the warrants for redemption as described above, the management will have the option to require any holder that wishes to exercise its warrant to do so on a “cashless basis.” If the management takes advantage of this option, all holders of warrants would pay the exercise price by surrendering their warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the excess of the “fair market value” (defined below) over the exercise price of the warrants by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants | Note 8 — Stockholders’ Equity Preferred Stock 1,000,000 0.0001 no Common Stock 50,000,000 0.0001 4,674,626 2,875,000 10,117,574 no The Company’s initial stockholder has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $ 12.50 |
Fair Value Measurements
Fair Value Measurements | 6 Months Ended |
Jun. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Note 9 — Fair Value Measurements The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at June 30, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis June 30, Quoted Significant Significant 2021 (Level 1) (Level 2) (Level 3) Assets: U.S. Money Market held in Trust Account $ 116,155,315 $ 116,155,315 $ — $ — Liabilities: Public Warrants Liability $ 5,289,425 $ 5,289,425 $ — $ — Private Placement Warrants Liability 241,681 — — 241,681 Fair value of liabilities $ 5,531,106 $ 5,289,425 $ — $ 241,681 The Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the Condensed Balance Sheet. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the Condensed Statement of Operations. The Company established the initial fair value of the Public Warrants and Private Warrants on January 14, 2021, the date of the Company’s Initial Public Offering, using a Monte Carlo simulation model. On June 30, 2021, the Company established the fair value of the Private Warrants using a Monto Carlo simulation model, and the fair value of the Public Warrants by reference to the quoted market price. The Public Warrants have traded on Nasdaq stock market since January 14, 2021 under the trading symbol BCYPW. The Public and Private Warrants were classified as Level 3 at June 30, 2021 and the Private Warrants were classified as Level 3 at June 30, 2021 due to the use of unobservable inputs. As of June 30, 2021, the Public Warrants were transferred to Level 1 due to the use of the quoted market price. The following table presents the changes in the fair value of the Level 3 liabilities: Schedule of Change in Fair Value Liabilities Private Placement Warrants Public Warrants Warrant Liabilities Fair Value as of December 31, 2020 $ — $ — $ — Initial measurement on January 14, 2021 249,963 6,775,220 7,025,183 Change in valuation (8,282 ) (1,485,795 ) (1,494,077 ) Transferred to Level 1 — (5,289,425 ) (5,289,425 ) Balance, June 30, 2021 $ 241,681 $ — $ 241,681 The key inputs into the Monte Carlo simulation as of January 14, 2021 and June 30, 2021 were as follows: Schedule of Key Inputs into Monte Carlo Simulation (Initial Measurement) Inputs January 14, 2021 June 30, 2021 Risk-free interest rate 0.60 % 0.90 % Expected term remaining (years) 5.67 5.19 Expected volatility 24.2 % 19.8 % Stock price $ 9.41 $ 9.96 |
Subsequent Events
Subsequent Events | 2 Months Ended | 6 Months Ended |
Dec. 31, 2020 | Jun. 30, 2021 | |
Subsequent Events [Abstract] | ||
Subsequent Events | Note 8 — Subsequent Events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements. On January 3, 2021, the Company effected a stock dividend of 1/3 of a share of common stock for every share of common stock outstanding, resulting in an aggregate of 2,875,000 375,000 28,750 28,750 0.008 230 2,630,625 244,375 343,125 31,875 375,000 On January 14, 2021, the Company the Company consummated the IPO of 11,500,000 1,500,000 10.00 115,000,000 417,200 10.00 4,172,000 6,038,360 1,529,500 4,220,500 288,360 On January 14, 2021, the Company paid the $ 150,000 | Note 10 — Subsequent Events None. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 2 Months Ended | 6 Months Ended |
Dec. 31, 2020 | Jun. 30, 2021 | |
Accounting Policies [Abstract] | ||
Basis of Presentation | Basis of Presentation The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). | Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on April 2, 2021, which contains the audited financial statements and notes thereto. The interim results for the three months and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending |
Emerging Growth Company Status | Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. | Emerging Growth Company Status The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. | Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did no | Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did no |
Marketable Securities Held in Trust Account | Marketable Securities Held in Trust Account At June 30, 2021, substantially all of the assets held in the Trust Account were held in money market funds which invest in U.S. Treasury securities. | |
Warrant Liabilities | Warrant Liabilities The Company evaluated the Public Warrants and Private Placement Warrants (collectively, “Warrants”, which are discussed in Note 2, Note 4, Note 5 and Note 9) in accordance with ASC 815-40, “Derivatives and Hedging — Contracts in Entity’s Own Equity”, and concluded that a provision in the Warrant Agreement related to certain tender or exchange offers precludes the Warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as derivative liabilities on the Condensed Balance Sheet and measured at fair value at inception (on the date of the IPO) and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in the Condensed Statement of Operations in the period of change. | |
Offering Costs Associated with the Initial Public Offering | Offering Costs Associated with the Initial Public Offering The Company complies with the requirements of the ASC 340-10-S99-1. Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred, presented as non-operating expenses in the statement of operations. Offering costs associated with the Class A common stock were charged to stockholders’ equity upon the completion of the Initial Public Offering. Transaction costs for the six month ended June 30, 2021 amounted to $ 6,108,360 359,874 | |
Common Stock Subject to Possible Redemption | Common Stock Subject to Possible Redemption The Company accounts for its common stock subject to possible redemption in accordance with the guidance in Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s condensed balance sheets. | |
Income Taxes | Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. The deferred tax assets were deemed to be de minimus as of December 31, 2020. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has identified the United States as its only “major” tax jurisdiction. The Company is subject to income tax examinations by major taxing authorities since inception. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. The provision for income taxes was deemed to be de minimus for the period from November 12, 2020 (inception) through December 31, 2020. | Income Taxes The Company accounts for income taxes under ASC 740, Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. The deferred tax assets were deemed to be de minimis as of June 30, 2021 and December 31, 2020. ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no |
Net Loss Per Common Stock | Net Loss Per Common Stock Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. Weighted average shares were reduced for the effect of an aggregate of 375,000 As a result of the underwriter’s election to fully exercise their over-allotment option on January 14, 2021, the 375,000 | Net Income Per Common Share Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The Company applies the two-class method in calculating earnings per share. Shares of common stock subject to possible redemption at June 30, 2021, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of basic net loss per common share since such shares, if redeemed, only participate in their pro rata share of the Trust Account earnings, less the Company’s portion available to pay taxes. The Company has not considered the effect of warrants sold in the Initial Public Offering and the private placement to purchase 5,958,600 Net Income per Common Share The Company’s net income is adjusted for the portion of income that is attributable to common stock subject to possible redemption, as these shares only participate in the earnings of the Trust Account and not the income or losses of the Company. Accordingly, basic and diluted loss per common share is calculated as follows: Schedule of Reconciliation of Net Income Per Common Share Three Months Six Months Common Stock Subject to Possible Redemption Numerator: Earnings allocable to common stock subject to possible redemption Interest earned on marketable securities held in Trust Account $ 2,896 $ 5,315 Less: Interest allocable to non-redeemable common stock (915 ) (1,680 ) Net income allocable to shares subject to possible redemption $ 1,981 $ 3,635 Denominator: Weighted Average Redeemable Class A Ordinary Shares Basic and diluted weighted average shares outstanding 10,333,213 10,363,269 Basic and diluted net income per share $ 0.00 $ 0.00 Non-Redeemable Common Stock Numerator: Net Income (Loss) Minus Net Earnings Net Income (Loss) $ (2,202,161 ) $ 771,059 Less: Income attributable to common stock subject to possible redemption (1,981 ) (3,635 ) Non-Redeemable net income (loss) $ (2,204,142 ) $ 767,424 Weighted average non-redeemable shares outstanding, basic and diluted 4,443,103 4,162,957 Basic and diluted net income (loss) per share $ (0.50 ) $ 0.18 |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the federal depository insurance coverage of $ 250,000 | Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the federal depository insurance coverage of $ 250,000 |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. | Fair Value of Financial Instruments The Company follows the guidance in ASC 820, “Fair Value Measurement,” for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1 — Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment. Level 2 — Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means. Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement. See Note 9 for additional information on assets and liabilities measured at fair value. |
Recently Adopted Accounting Standards | Recently Adopted Accounting Standards In August 2020, the FASB issued ASU 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company early adopted ASU 2020-06 on January 1, 2021. Adoption of the ASU did not impact the Company’s financial position, results of operations or cash flows. | |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements. | Recent Accounting Pronouncements Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements. |
Deferred Offering Costs | Deferred Offering Costs Deferred offering costs consist of legal, accounting and other expenses incurred through the balance sheet date that are directly related to the IPO and that will be charged to stockholders’ equity upon the completion of the IPO. |
Restatement of Previously Iss_2
Restatement of Previously Issued Financial Statements (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Changes and Error Corrections [Abstract] | |
Schedule of Restatement of Balance Sheet | Schedule of Restatement of Balance Sheet As of January 14, 2021 As Previously Restatement As Restated Balance Sheet as of January 14, 2021 Total assets $ 117,645,054 $ — $ 117,645,045 Liabilities and stockholders’ equity Total current liabilities $ 267,540 $ — $ 267,540 Stock warrant liabilities — 7,025,183 7,025,183 Total liabilities $ 4,488,040 7,025,183 11,513,223 Class A common stock, $ 0.0001 108,157,010 (7,025,183 ) 101,131,827 Stockholders’ equity Preferred stock- $ 0.0001 — — — Common stock - $ 0.0001 398 81 479 Additional paid-in-capital 5,003,838 355,669 5,359,507 Accumulated deficit (4,232 ) (355,750 ) (359,982 ) Total stockholders’ equity 5,000,004 — 5,000,004 Total liabilities and stockholders’ equity $ 117,645,054 $ — $ 117,645,054 |
Significant Accounting Polici_3
Significant Accounting Policies (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Schedule of Reconciliation of Net Income Per Common Share | The Company’s net income is adjusted for the portion of income that is attributable to common stock subject to possible redemption, as these shares only participate in the earnings of the Trust Account and not the income or losses of the Company. Accordingly, basic and diluted loss per common share is calculated as follows: Schedule of Reconciliation of Net Income Per Common Share Three Months Six Months Common Stock Subject to Possible Redemption Numerator: Earnings allocable to common stock subject to possible redemption Interest earned on marketable securities held in Trust Account $ 2,896 $ 5,315 Less: Interest allocable to non-redeemable common stock (915 ) (1,680 ) Net income allocable to shares subject to possible redemption $ 1,981 $ 3,635 Denominator: Weighted Average Redeemable Class A Ordinary Shares Basic and diluted weighted average shares outstanding 10,333,213 10,363,269 Basic and diluted net income per share $ 0.00 $ 0.00 Non-Redeemable Common Stock Numerator: Net Income (Loss) Minus Net Earnings Net Income (Loss) $ (2,202,161 ) $ 771,059 Less: Income attributable to common stock subject to possible redemption (1,981 ) (3,635 ) Non-Redeemable net income (loss) $ (2,204,142 ) $ 767,424 Weighted average non-redeemable shares outstanding, basic and diluted 4,443,103 4,162,957 Basic and diluted net income (loss) per share $ (0.50 ) $ 0.18 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis June 30, Quoted Significant Significant 2021 (Level 1) (Level 2) (Level 3) Assets: U.S. Money Market held in Trust Account $ 116,155,315 $ 116,155,315 $ — $ — Liabilities: Public Warrants Liability $ 5,289,425 $ 5,289,425 $ — $ — Private Placement Warrants Liability 241,681 — — 241,681 Fair value of liabilities $ 5,531,106 $ 5,289,425 $ — $ 241,681 |
Schedule of Change in Fair Value Liabilities | The following table presents the changes in the fair value of the Level 3 liabilities: Schedule of Change in Fair Value Liabilities Private Placement Warrants Public Warrants Warrant Liabilities Fair Value as of December 31, 2020 $ — $ — $ — Initial measurement on January 14, 2021 249,963 6,775,220 7,025,183 Change in valuation (8,282 ) (1,485,795 ) (1,494,077 ) Transferred to Level 1 — (5,289,425 ) (5,289,425 ) Balance, June 30, 2021 $ 241,681 $ — $ 241,681 |
Schedule of Key Inputs into Monte Carlo Simulation | The key inputs into the Monte Carlo simulation as of January 14, 2021 and June 30, 2021 were as follows: Schedule of Key Inputs into Monte Carlo Simulation (Initial Measurement) Inputs January 14, 2021 June 30, 2021 Risk-free interest rate 0.60 % 0.90 % Expected term remaining (years) 5.67 5.19 Expected volatility 24.2 % 19.8 % Stock price $ 9.41 $ 9.96 |
Organization and Business Ope_2
Organization and Business Operations (Details Narrative) - USD ($) | Jun. 21, 2021 | Jan. 14, 2021 | Nov. 20, 2020 | Dec. 31, 2020 | Mar. 31, 2021 | Jun. 30, 2021 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Units issued during the period, shares | 2,156,250 | |||||
Unit issued price | $ 0.012 | |||||
Description of units | In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Company’s sponsor or its affiliates, without taking into account any founder shares held by the Company’s sponsor or its affiliates, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination on the date of the consummation of the initial business combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial business combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. | |||||
Pro rata interest | $ 10.10 | |||||
Agreement description | In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or business combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $ | The Company’s initial stockholder has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and not to transfer, assign or sell the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. Any permitted transferees will be subject to the same restrictions and other agreements of the Company’s initial stockholders with respect to any founder shares. | The Company’s initial stockholder has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and not to transfer, assign or sell the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. Any permitted transferees will be subject to the same restrictions and other agreements of the Company’s initial stockholders with respect to any founder shares. | |||
Common stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||
Common stock value | $ 25,000 | $ 109,251,515 | ||||
[custom:AddtionalConsiderationOnEarnoutSharesDescription] | (A) 25% of the Earnout Shares, if the VWAP (as defined in the Business Combination Agreement) of Company Shares is greater than or equal to $15.00 for any twenty (20) Trading Days (as defined in the Business Combination Agreement) within a period of thirty (30) consecutive Trading Days, (B) 25% of the Earnout Shares, if the VWAP of Company Shares is greater than or equal to $20.00 for any twenty (20) Trading Days within a period of thirty (30) consecutive Trading Days, (C) 25% of the Earnout Shares, if the VWAP of Company Shares is greater than or equal to $25.00 for any twenty (20) Trading Days within a period of thirty (30) consecutive Trading Days, and (D) 25% of the Earnout Shares, if the VWAP of Company Shares is greater than or equal to $30.00 for any twenty (20) Trading Days within a period of thirty (30) consecutive Trading Days. | |||||
Cash | $ 1,200,000 | $ 84,836 | $ 756,803 | |||
Working capital deficit | 219,107 | |||||
Unsecured promissory note | 1,200,000 | 150,000 | ||||
Business Combination Agreement [Member] | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Common stock, par value | $ 0.0001 | |||||
Common stock value | $ 300,000,000 | |||||
Maximum [Member] | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Interest to pay dissolution expenses | $ 100,000 | |||||
Sponsor [Member] | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Capital contribution | $ 25,000 | |||||
Sponsor [Member] | Closing of the IPO [Member] | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Unit issued price | $ 10 | $ 10 | $ 10 | |||
Sale of units | 417,200 | 417,200 | 417,200 | |||
Proceeds from sale of units | $ 4,172,000 | $ 4,172,000 | $ 4,172,000 | |||
Common Stock [Member] | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Units issued during the period, shares | 11,500,000 | |||||
Unit issued price | $ 11.50 | $ 12.50 | ||||
Common stock value | $ 1,150 | |||||
Warrant [Member] | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Warrant liability expense | $ 359,874 | |||||
IPO [Member] | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Units issued during the period, shares | 11,500,000 | |||||
Unit issued price | $ 10 | |||||
Description of units | Each Unit consists of one share of common stock, and one-half redeemable warrant to purchase one share of common stock at a price of $11.50 per whole share. | |||||
Proceeds from sale of units | $ 116,150,000 | |||||
Transaction costs | 6,038,360 | 6,108,360 | ||||
Underwriting fee | 1,529,500 | 1,529,500 | ||||
Deferred underwriting fee | 4,220,500 | 4,220,500 | ||||
Other offering costs | $ 288,360 | $ 358,360 | ||||
Agreement description | The Company will have 15 months (or up to 21 months) from the closing of the IPO on January 14, 2021 to consummate a Business Combination (the “Combination Period”). However, if the Company is unable to complete a Business Combination within the Combination Period,the Company will redeem 100% of the outstanding public shares for a pro rata portion of the funds held in the trust account, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to the Company to pay its franchise and income taxes, divided by the number of then outstanding public shares, subject to applicable law and as further described in the registration statement, and then seek to dissolve and liquidate. | |||||
Agreement description | The Company will have 15 months (or up to 21 months) from the closing of the IPO to consummate a Business Combination (the “Combination Period”). However, if the Company is unable to complete a Business Combination within the Combination Period, the Company will redeem 100% of the outstanding public shares for a pro rata portion of the funds held in the trust account, equal to the aggregate amount then on deposit in the trust account including interest earned on the funds held in the trust account and not previously released to the Company to pay its franchise and income taxes, divided by the number of then outstanding public shares, subject to applicable law and as further described in registration statement, and then seek to dissolve and liquidate. | |||||
Over-Allotment Option [Member] | ||||||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
Units issued during the period, shares | 1,500,000 | |||||
Unit issued price | $ 10 | |||||
Proceeds from IPO | $ 115,000,000 |
Schedule of Restatement of Bala
Schedule of Restatement of Balance Sheet (Details) - USD ($) | Jun. 30, 2021 | Mar. 31, 2021 | Jan. 14, 2021 | Dec. 31, 2020 | Nov. 11, 2020 | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||
Total assets | $ 117,091,985 | $ 117,645,045 | $ 322,205 | |||
Total current liabilities | 152,879 | 267,540 | 306,201 | |||
Stock warrant liabilities | 5,531,106 | 7,025,183 | ||||
Total liabilities | 9,904,485 | 11,513,223 | 306,201 | |||
Class A common stock, $0.0001 par value; shares subject to possible redemption | 101,131,827 | |||||
Preferred stock- $0.0001 par value | ||||||
Common stock - $0.0001 par value | 467 | 479 | 288 | [1] | ||
Additional paid-in-capital | 4,237,471 | 5,359,507 | 24,712 | |||
Accumulated deficit | 762,063 | (359,982) | (8,996) | |||
Total stockholders' equity | 5,000,001 | $ 5,000,005 | 5,000,004 | 16,004 | ||
Total liabilities and stockholders' equity | $ 117,091,985 | 117,645,054 | $ 322,205 | |||
Previously Reported [Member] | ||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||
Total assets | 117,645,054 | |||||
Total current liabilities | 267,540 | |||||
Stock warrant liabilities | ||||||
Total liabilities | 4,488,040 | |||||
Class A common stock, $0.0001 par value; shares subject to possible redemption | 108,157,010 | |||||
Preferred stock- $0.0001 par value | ||||||
Common stock - $0.0001 par value | 398 | |||||
Additional paid-in-capital | 5,003,838 | |||||
Accumulated deficit | (4,232) | |||||
Total stockholders' equity | 5,000,004 | |||||
Total liabilities and stockholders' equity | 117,645,054 | |||||
Revision of Prior Period, Adjustment [Member] | ||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||||||
Total assets | ||||||
Total current liabilities | ||||||
Stock warrant liabilities | 7,025,183 | |||||
Total liabilities | 7,025,183 | |||||
Class A common stock, $0.0001 par value; shares subject to possible redemption | (7,025,183) | |||||
Preferred stock- $0.0001 par value | ||||||
Common stock - $0.0001 par value | 81 | |||||
Additional paid-in-capital | 355,669 | |||||
Accumulated deficit | (355,750) | |||||
Total stockholders' equity | ||||||
Total liabilities and stockholders' equity | ||||||
[1] | Includes up to 343,125 31,875 ). As a result of the underwriter’s election to fully exercise their over-allotment option on January 14, 2021, the founder shares and representative shares are no longer subject to forfeiture (see Note 8). |
Schedule of Restatement of Ba_2
Schedule of Restatement of Balance Sheet (Details) (Parenthetical) - $ / shares | Jun. 30, 2021 | Jan. 14, 2021 | Dec. 31, 2020 |
Affiliate, Collateralized Security [Line Items] | |||
Common stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 |
Preferred stock, par value | $ 0.0001 | 0.0001 | $ 0.0001 |
Common Class A [Member] | |||
Affiliate, Collateralized Security [Line Items] | |||
Common stock, par value | $ 0.0001 |
Restatement of Previously Iss_3
Restatement of Previously Issued Financial Statements (Details Narrative) - USD ($) | Jan. 14, 2021 | Jun. 30, 2021 | Jun. 30, 2021 |
Affiliate, Collateralized Security [Line Items] | |||
Change in fair value of warrant liabilities | $ 1,948,210 | $ (1,494,077) | |
Public and Private Warrants [Member] | |||
Affiliate, Collateralized Security [Line Items] | |||
Change in fair value of warrant liabilities | $ 7,000,000 | ||
IPO Transaction costs | $ 355,750 |
Schedule of Reconciliation of N
Schedule of Reconciliation of Net Income Per Common Share (Details) - USD ($) | 2 Months Ended | 3 Months Ended | 6 Months Ended | ||||
Dec. 31, 2020 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2021 | ||||
Accounting Policies [Abstract] | |||||||
Interest earned on marketable securities held in Trust Account | $ 2,896 | $ 5,315 | |||||
Less: Interest allocable to non-redeemable common stock | (915) | (1,680) | |||||
Net income allocable to shares subject to possible redemption | $ 1,981 | $ 3,635 | |||||
Basic and diluted weighted average shares outstanding | 10,333,213 | 10,363,269 | |||||
Basic and diluted net income per share | $ 0 | $ 0 | |||||
Net Income (Loss) | $ (8,996) | $ (2,202,161) | $ 2,973,220 | $ 771,059 | |||
Less: Income attributable to common stock subject to possible redemption | (1,981) | (3,635) | |||||
Non-Redeemable net income (loss) | $ (2,204,142) | $ 767,424 | |||||
Weighted average non-redeemable shares outstanding, basic and diluted | 2,500,000 | [1] | 4,443,103 | [2] | 4,162,957 | [2] | |
Basic and diluted net income (loss) per share | $ 0 | $ (0.50) | $ 0.18 | ||||
[1] | Excludes up to 343,125 31,875 As a result of the underwriter’s election to fully exercise their over-allotment option on January 14, 2021, the founder shares and representative shares are no longer subject to forfeiture (see Note 8). | ||||||
[2] | Excludes an aggregate of 10,117,574 |
Significant Accounting Polici_4
Significant Accounting Policies (Details Narrative) - USD ($) | Jan. 14, 2021 | Dec. 31, 2020 | Jun. 30, 2021 |
Subsidiary, Sale of Stock [Line Items] | |||
Cash equivalents | $ 0 | $ 0 | |
Unrecognized Tax Benefits, Income Tax Penalties Accrued | 0 | 0 | |
Stock Issued | 101,131,827 | ||
Cash FDIC amount | $ 250,000 | 250,000 | |
Shares forfeited during the period | 375,000 | ||
Warrant [Member] | |||
Subsidiary, Sale of Stock [Line Items] | |||
Warrant liability expense | 359,874 | ||
IPO [Member] | |||
Subsidiary, Sale of Stock [Line Items] | |||
Sale of Stock, Consideration Received Per Transaction | $ 6,038,360 | 6,108,360 | |
Private Placement [Member] | Warrant [Member] | |||
Subsidiary, Sale of Stock [Line Items] | |||
Stock Issued | $ 5,958,600 | ||
Over-Allotment Option [Member] | |||
Subsidiary, Sale of Stock [Line Items] | |||
Shares exercised during the period | 375,000 |
Initial Public Offering (Detail
Initial Public Offering (Details Narrative) - $ / shares | Jan. 14, 2021 | Nov. 20, 2020 | Mar. 31, 2021 | Jun. 30, 2021 | Dec. 31, 2020 |
Subsidiary, Sale of Stock [Line Items] | |||||
Units issued during the period, shares | 2,156,250 | ||||
Unit issued price | $ 0.012 | ||||
Sale of Stock, Description of Transaction | In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Company’s sponsor or its affiliates, without taking into account any founder shares held by the Company’s sponsor or its affiliates, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination on the date of the consummation of the initial business combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial business combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. | ||||
Warrant price | $ 0.01 | $ 0.01 | |||
Description of redemption of warrants | the reported last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption to the warrant holders. | ||||
Common Stock [Member] | |||||
Subsidiary, Sale of Stock [Line Items] | |||||
Units issued during the period, shares | 11,500,000 | ||||
Unit issued price | $ 11.50 | $ 12.50 | |||
IPO [Member] | |||||
Subsidiary, Sale of Stock [Line Items] | |||||
Units issued during the period, shares | 11,500,000 | ||||
Unit issued price | $ 10 | ||||
Sale of Stock, Description of Transaction | Each Unit consists of one share of common stock, and one-half redeemable warrant to purchase one share of common stock at a price of $11.50 per whole share. | ||||
Over-Allotment Option [Member] | |||||
Subsidiary, Sale of Stock [Line Items] | |||||
Units issued during the period, shares | 1,500,000 | ||||
Unit issued price | $ 10 |
Private Placement (Details Narr
Private Placement (Details Narrative) - USD ($) | Jan. 14, 2021 | Dec. 31, 2020 | Jun. 30, 2021 | Nov. 20, 2020 |
Subsidiary, Sale of Stock [Line Items] | ||||
Unit issued price | $ 0.012 | |||
Sponsor [Member] | Closing of the IPO [Member] | ||||
Subsidiary, Sale of Stock [Line Items] | ||||
Sale of units | 417,200 | 417,200 | 417,200 | |
Unit issued price | $ 10 | $ 10 | $ 10 | |
Proceeds from sale of units | $ 4,172,000 | $ 4,172,000 | $ 4,172,000 |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | Dec. 07, 2021 | Jan. 14, 2021 | Jan. 14, 2021 | Jan. 04, 2021 | Jan. 04, 2021 | Jan. 03, 2021 | Dec. 07, 2020 | Nov. 20, 2020 | Nov. 19, 2020 | Nov. 19, 2020 | Nov. 13, 2020 | Dec. 31, 2020 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2021 |
Related Party Transaction [Line Items] | |||||||||||||||
Units issued during the period, shares | 2,156,250 | ||||||||||||||
Stock issued during the period | $ 25,000 | $ 109,251,515 | |||||||||||||
Shares issued price per share | $ 0.012 | ||||||||||||||
Shares forfeited during the period | 375,000 | ||||||||||||||
Common stock, shares outstanding | 2,875,000 | 4,674,626 | 4,674,626 | ||||||||||||
Shares exercised during the period | 375,000 | 375,000 | |||||||||||||
Agreement description | In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or business combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $ | The Company’s initial stockholder has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and not to transfer, assign or sell the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. Any permitted transferees will be subject to the same restrictions and other agreements of the Company’s initial stockholders with respect to any founder shares. | The Company’s initial stockholder has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and not to transfer, assign or sell the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. Any permitted transferees will be subject to the same restrictions and other agreements of the Company’s initial stockholders with respect to any founder shares. | ||||||||||||
Proceeds from issuance of promissory note to related party | $ 150,000 | $ 150,000 | |||||||||||||
Debt conversion description | Up to $1,500,000 of such Working Capital Loans may be convertible into units at a price of $10.00 per unit at the option of the lender, upon consummation of the Company’s Initial Business Combination. | Up to $1,500,000 of such Working Capital Loans may be convertible into units at a price of $10.00 per unit at the option of the lender, upon consummation of the Company’s Initial Business Combination. | |||||||||||||
Service fee expense | $ 7,742 | $ 30,000 | $ 60,000 | ||||||||||||
Over-Allotment Option [Member] | |||||||||||||||
Related Party Transaction [Line Items] | |||||||||||||||
Units issued during the period, shares | 1,500,000 | ||||||||||||||
Shares issued price per share | $ 10 | $ 10 | |||||||||||||
Founder Shares [Member] | |||||||||||||||
Related Party Transaction [Line Items] | |||||||||||||||
Shares forfeited during the period | 375,000 | ||||||||||||||
Common stock, shares outstanding | 2,875,000 | ||||||||||||||
Founder Shares [Member] | Over-Allotment Option [Member] | |||||||||||||||
Related Party Transaction [Line Items] | |||||||||||||||
Shares exercised during the period | 375,000 | ||||||||||||||
Sponsor [Member] | |||||||||||||||
Related Party Transaction [Line Items] | |||||||||||||||
Shares forfeited during the period | 343,125 | ||||||||||||||
Common stock, shares outstanding | 2,630,625 | 2,630,625 | |||||||||||||
Debt instrument maturity date | This loan is non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the IPO. | This loan was non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the IPO. | |||||||||||||
Monthly fee | $ 10,000 | $ 10,000 | |||||||||||||
Sponsor [Member] | Maximum [Member] | |||||||||||||||
Related Party Transaction [Line Items] | |||||||||||||||
Unsecured promissory note | $ 250,000 | $ 250,000 | |||||||||||||
Sponsor [Member] | Founder Shares [Member] | |||||||||||||||
Related Party Transaction [Line Items] | |||||||||||||||
Units issued during the period, shares | 2,156,250 | ||||||||||||||
Stock issued during the period | $ 25,000 | ||||||||||||||
Shares issued price per share | $ 0.012 | ||||||||||||||
Shares forfeited during the period | 161,719 | 28,750 | 161,719 | ||||||||||||
Shares owned | 2,630,625 | ||||||||||||||
Agreement description | The Sponsor has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. | The Sponsor has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. | |||||||||||||
Ladenburg and Certain Employees [Member] | |||||||||||||||
Related Party Transaction [Line Items] | |||||||||||||||
Shares forfeited during the period | 31,875 | ||||||||||||||
Ladenburg and Certain Employees [Member] | Representative Shares [Member] | |||||||||||||||
Related Party Transaction [Line Items] | |||||||||||||||
Units issued during the period, shares | 161,719 | 28,750 | 161,719 | ||||||||||||
Stock issued during the period | $ 1,875 | $ 230 | $ 1,875 | ||||||||||||
Shares issued price per share | $ 0.012 | $ 0.008 | $ 0.008 | $ 0.012 | |||||||||||
Shares forfeited during the period | 28,750 | 31,875 | |||||||||||||
Common stock, shares outstanding | 244,375 | 244,375 | |||||||||||||
Shares exercised during the period | 28,750 | 31,875 | |||||||||||||
Shares owned | 244,375 |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) - USD ($) | Jan. 14, 2021 | Nov. 20, 2020 |
Subsidiary, Sale of Stock [Line Items] | ||
Units issued during the period, shares | 2,156,250 | |
Over-Allotment Option [Member] | ||
Subsidiary, Sale of Stock [Line Items] | ||
Units issued during the period, shares | 1,500,000 | |
Gross proceeds from IPO | $ 115,000,000 | |
Over-Allotment Option [Member] | Underwriting Agreement [Member] | ||
Subsidiary, Sale of Stock [Line Items] | ||
Units issued during the period, shares | 1,500,000 | |
IPO [Member] | ||
Subsidiary, Sale of Stock [Line Items] | ||
Units issued during the period, shares | 11,500,000 | |
IPO [Member] | Underwriters [Member] | ||
Subsidiary, Sale of Stock [Line Items] | ||
Units issued during the period, shares | 1,500,000 | |
Cash underwriting fee, percentage | 1.33% | |
Gross proceeds from IPO | $ 1,529,500 | |
Deferred underwriting fee, percentage | 3.67% | |
Proceeds from deferred underwriting | $ 4,220,500 |
Stockholders_ Equity (Details N
Stockholders’ Equity (Details Narrative) - USD ($) | Dec. 07, 2021 | Jan. 14, 2021 | Jan. 04, 2021 | Jan. 04, 2021 | Jan. 03, 2021 | Dec. 07, 2020 | Nov. 20, 2020 | Nov. 13, 2020 | Dec. 31, 2020 | Mar. 31, 2021 | Jun. 30, 2021 | Dec. 31, 2020 |
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||
Preferred stock, shares authorized | 1,000,000 | 1,000,000 | 1,000,000 | |||||||||
Preferred stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||
Preferred stock, shares issued | 0 | 0 | 0 | |||||||||
Preferred stock, shares outstanding | 0 | 0 | 0 | |||||||||
Common stock, shares authorized | 50,000,000 | 50,000,000 | 50,000,000 | |||||||||
Common stock, par value | $ 0.0001 | $ 0.0001 | $ 0.0001 | $ 0.0001 | ||||||||
Common stock, shares issued | 2,875,000 | 4,674,626 | 2,875,000 | |||||||||
Common stock, shares outstanding | 2,875,000 | 4,674,626 | 2,875,000 | |||||||||
Common stock shares redemption | 10,117,574 | 0 | ||||||||||
Agreement description | In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or business combination agreement, reduce the amount of funds in the trust account to below the lesser of (i) $ | The Company’s initial stockholder has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and not to transfer, assign or sell the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. Any permitted transferees will be subject to the same restrictions and other agreements of the Company’s initial stockholders with respect to any founder shares. | The Company’s initial stockholder has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and not to transfer, assign or sell the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. Any permitted transferees will be subject to the same restrictions and other agreements of the Company’s initial stockholders with respect to any founder shares. | |||||||||
Shares issued price per share | $ 0.012 | |||||||||||
Units issued during the period, shares | 2,156,250 | |||||||||||
Stock issued during the period | $ 25,000 | $ 109,251,515 | ||||||||||
Shares forfeited during the period | 375,000 | |||||||||||
Shares exercised during the period | 375,000 | 375,000 | ||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||
Warrant [Member] | ||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||
Agreement description | In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial business combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of any such issuance to the Company’s Sponsor or its affiliates, without taking into account any founder shares held by the Company’s Sponsor or its affiliates, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination on the date of the consummation of the initial business combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates the initial business combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described below under “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. | |||||||||||
Sponsor [Member] | ||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||
Common stock, shares outstanding | 2,630,625 | 2,630,625 | ||||||||||
Shares forfeited during the period | 343,125 | |||||||||||
Ladenburg and Certain Employees [Member] | ||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||
Shares forfeited during the period | 31,875 | |||||||||||
Common Stock [Member] | ||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||
Shares issued price per share | $ 11.50 | $ 12.50 | ||||||||||
Units issued during the period, shares | 11,500,000 | |||||||||||
Stock issued during the period | $ 1,150 | |||||||||||
Founder Shares [Member] | ||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||
Common stock, shares outstanding | 2,875,000 | |||||||||||
Shares forfeited during the period | 375,000 | |||||||||||
Founder Shares [Member] | Sponsor [Member] | ||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||
Agreement description | The Sponsor has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. | The Sponsor has agreed not to transfer, assign or sell 50% of its founder shares until the earlier to occur of (A) six months after the completion of the Company’s initial business combination or (B) the date the last sale price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the Company’s initial business combination, and the remaining 50% of the founder shares until six months after the completion of the Company’s initial business combination, or earlier, if, in either case, subsequent to the Company’s initial business combination, the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. | ||||||||||
Shares issued price per share | $ 0.012 | |||||||||||
Units issued during the period, shares | 2,156,250 | |||||||||||
Stock issued during the period | $ 25,000 | |||||||||||
Shares forfeited during the period | 161,719 | 28,750 | 161,719 | |||||||||
Founder Shares [Member] | Sponsor [Member] | ||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||
Shares forfeited during the period | 161,719 | |||||||||||
Representative Shares [Member] | Ladenburg and Certain Employees [Member] | ||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||
Common stock, shares outstanding | 244,375 | 244,375 | ||||||||||
Shares issued price per share | $ 0.012 | $ 0.008 | $ 0.008 | $ 0.012 | ||||||||
Units issued during the period, shares | 161,719 | 28,750 | 161,719 | |||||||||
Stock issued during the period | $ 1,875 | $ 230 | $ 1,875 | |||||||||
Shares forfeited during the period | 28,750 | 31,875 | ||||||||||
Shares exercised during the period | 28,750 | 31,875 | ||||||||||
Representative Shares [Member] | Ladenburg and Certain Employees [Member] | ||||||||||||
Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||||||||||
Shares issued price per share | $ 0.012 | |||||||||||
Units issued during the period, shares | 161,719 | |||||||||||
Stock issued during the period | $ 1,875 |
Schedule of Fair Value, Assets
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) | Jun. 30, 2021 | Jan. 14, 2021 | Dec. 31, 2020 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
U.S. Money Market held in Trust Account | $ 116,155,315 | ||
Public Warrants Liability | 5,289,425 | ||
Private Placement Warrants Liability | 241,681 | ||
Fair value of liabilities | 5,531,106 | $ 7,025,183 | |
Fair Value, Inputs, Level 1 [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
U.S. Money Market held in Trust Account | 116,155,315 | ||
Public Warrants Liability | 5,289,425 | ||
Private Placement Warrants Liability | |||
Fair value of liabilities | 5,289,425 | ||
Fair Value, Inputs, Level 2 [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
U.S. Money Market held in Trust Account | |||
Public Warrants Liability | |||
Private Placement Warrants Liability | |||
Fair value of liabilities | |||
Fair Value, Inputs, Level 3 [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
U.S. Money Market held in Trust Account | |||
Public Warrants Liability | |||
Private Placement Warrants Liability | 241,681 | ||
Fair value of liabilities | $ 241,681 |
Schedule of Change in Fair Valu
Schedule of Change in Fair Value Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] | 6 Months Ended |
Jun. 30, 2021USD ($) | |
Private Placement Warrants [Member] | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Fair Value Beginning | |
Initial Measurement | 249,963 |
Change in valuation | (8,282) |
Transferred to Level 1 | |
Fair value of liabilities | 241,681 |
Public Warrants [Member] | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Fair Value Beginning | |
Initial Measurement | 6,775,220 |
Change in valuation | (1,485,795) |
Transferred to Level 1 | (5,289,425) |
Fair value of liabilities | |
Warrants Liabilities [Member] | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |
Fair Value Beginning | |
Initial Measurement | 7,025,183 |
Change in valuation | (1,494,077) |
Transferred to Level 1 | (5,289,425) |
Fair value of liabilities | $ 241,681 |
Schedule of Key Inputs into Mon
Schedule of Key Inputs into Monte Carlo Simulation (Details) - $ / shares | Jan. 14, 2021 | Jun. 30, 2021 |
Fair Value Disclosures [Abstract] | ||
Risk-free interest rate | 0.60% | 0.90% |
Expected term remaining (years) | 5 years 8 months 1 day | 5 years 2 months 8 days |
Expected volatility | 24.20% | 19.80% |
Stock price | $ 9.41 | $ 9.96 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) - USD ($) | Dec. 07, 2021 | Jan. 14, 2021 | Jan. 14, 2021 | Jan. 04, 2021 | Jan. 03, 2021 | Dec. 07, 2020 | Nov. 20, 2020 | Nov. 13, 2020 | Dec. 31, 2020 | Mar. 31, 2021 | Jun. 30, 2021 |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||||||||
Common stock, shares outstanding | 2,875,000 | 4,674,626 | |||||||||
Shares forfeited during the period | 375,000 | ||||||||||
Units issued during the period, shares | 2,156,250 | ||||||||||
Shares issued price per share | $ 0.012 | ||||||||||
Stock issued during the period | $ 25,000 | $ 109,251,515 | |||||||||
Shares exercised during the period | 375,000 | 375,000 | |||||||||
Proceeds from issuance of promissory note to related party | $ 150,000 | $ 150,000 | |||||||||
IPO [Member] | |||||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||||||||
Units issued during the period, shares | 11,500,000 | ||||||||||
Shares issued price per share | $ 10 | $ 10 | |||||||||
Proceeds from sale of units | $ 116,150,000 | ||||||||||
Transaction costs | 6,038,360 | $ 6,108,360 | |||||||||
Underwriting fee | 1,529,500 | 1,529,500 | |||||||||
Deferred underwriting fee | $ 4,220,500 | 4,220,500 | 4,220,500 | ||||||||
Other offering costs | $ 288,360 | 288,360 | $ 358,360 | ||||||||
Proceeds from issuance of promissory note to related party | $ 150,000 | ||||||||||
Over-Allotment Option [Member] | |||||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||||||||
Units issued during the period, shares | 1,500,000 | ||||||||||
Shares issued price per share | $ 10 | $ 10 | |||||||||
Proceeds from IPO | $ 115,000,000 | ||||||||||
Sponsor [Member] | |||||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||||||||
Common stock, shares outstanding | 2,630,625 | ||||||||||
Shares forfeited during the period | 343,125 | ||||||||||
Sponsor [Member] | Closing of the IPO [Member] | |||||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||||||||
Shares issued price per share | $ 10 | $ 10 | $ 10 | $ 10 | |||||||
Sale of units | 417,200 | 417,200 | 417,200 | ||||||||
Proceeds from sale of units | $ 4,172,000 | $ 4,172,000 | $ 4,172,000 | ||||||||
Ladenburg and Certain Employees [Member] | |||||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||||||||
Shares forfeited during the period | 31,875 | ||||||||||
Founder Shares [Member] | |||||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||||||||
Common stock, shares outstanding | 2,875,000 | ||||||||||
Shares forfeited during the period | 375,000 | ||||||||||
Founder Shares [Member] | Over-Allotment Option [Member] | |||||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||||||||
Shares exercised during the period | 375,000 | ||||||||||
Founder Shares [Member] | Sponsor [Member] | |||||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||||||||
Shares forfeited during the period | 161,719 | 28,750 | 161,719 | ||||||||
Units issued during the period, shares | 2,156,250 | ||||||||||
Shares issued price per share | $ 0.012 | ||||||||||
Stock issued during the period | $ 25,000 | ||||||||||
Representative Shares [Member] | Ladenburg and Certain Employees [Member] | |||||||||||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||||||||||
Common stock, shares outstanding | 244,375 | ||||||||||
Shares forfeited during the period | 28,750 | 31,875 | |||||||||
Units issued during the period, shares | 161,719 | 28,750 | 161,719 | ||||||||
Shares issued price per share | $ 0.012 | $ 0.008 | $ 0.012 | ||||||||
Stock issued during the period | $ 1,875 | $ 230 | $ 1,875 | ||||||||
Shares exercised during the period | 28,750 | 31,875 |